Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 116

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 116
---
 repair of articular cartilage defects in the knee caused by acute trauma or repetitive use. It is delivered directly to fill the
injury site using a delivery device, Stelar, which seals the lesion during the procedure, and through which the GelrinC liquid is delivered,
and from which the curing UV light is projected. Once the liquid GelrinC has filled the defect, it is cured in place into an elastomeric
implant by photo-curing under UV light for 90 seconds. The implant then starts eroding in conjunction with the advancing cartilage tissue
from the outside edges of the lesion inward. Following a period of approximately six to nine months, the implant is completely eroded,
resorbed and the injury’s surface is covered by newly formed hyaline-like cartilage produced by the patient’s own body. The
primary mode of action of GelrinC is presenting a smooth, impenetrable, neutral surface to the reproduced cartilage cells. The enabling
surface erosion completes this mechanism with a receding implant in a planned synchrony with the newly formed cartilage tissue.

<div align='center'>70</div>

Mode of Action of GelrinC:

| 1. Stelar delivery device membrane covers cartilage lesion. Using a syringe GelrinC is introduced into the lesion.                                                     |     | 2. Upon filing of the lesion, UV beam cures GelrinC into a soft rubbery implant.                                            |
| 3. As GelrinC implant recedes and resorbs, the cartilage lesion rim creates aggregates and new cartilage tissue filling up the void created by the retreating implant. |     | 4. At the end of 6-9 months with functioning knee, GelrinC implant is resorbed and new cartilage covers the treated lesion. |

<div align='center'>71</div>

As demonstrated in the Pilot
Study, the advantages of GelrinC include:

| ● | An off-the-shelf product for cartilage repair; |

| ● | A new class of a-cellular product solution; |

| ● | Polyethylene glycol, or PEG, implant preventing cellular migration as a primary mode of action and further aided by denatured fibrinogen controlled erosion for the regeneration of hyaline-like cartilage; |

| ● | Initial state as liquid form provides for complete and optimal defect filling and subsequent curing hardens it into a more solid body, and holding it in place; |

| ●